Sequencing Antibody Drug Conjugates in ER+/HER2 LOW MBC

PHASE2RecruitingINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

June 17, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

December 31, 2026

Conditions
Breast CancerMetastatic Breast CancerAdvanced Breast CancerHormone-receptor-positive Breast CancerHuman Epidermal Growth Factor 2 Low Breast Cancer
Interventions
DRUG

Sacituzumab govitecan

IV infusion of 10 mg/kg on Days 1 and 8 of each continuous and consecutive 21-day cycles. The first infusion will last approximately 3 hours and subsequent infusions will last 1-2 hours if prior infusions were well tolerated.

Trial Locations (3)

30322

NOT_YET_RECRUITING

Winship Cancer Institute at Emory University, Atlanta

33176

RECRUITING

Miami Cancer Institute at Baptist Health, Inc., Miami

90404

NOT_YET_RECRUITING

UCLA Jonsson Comprehensive Cancer Center, Los Angeles

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Gilead Sciences

INDUSTRY

lead

Reshma L. Mahtani, D.O.

OTHER